Filippo Jacobio

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

Retrieved on: 
Sunday, October 22, 2023
Incidence, ESMO, Progression-free survival, Trae Waynes, DCR, Colorectal cancer, PFS, Hospital, KRAS, Medicine, Observation, Quality of life, Clinical trial, Peking Union Medical College, Pancreatic cancer, ORR, Lung cancer, SHP2, Safety, European Society for Medical Oncology, Patient, Fuda Cancer Hospital-Guangzhou, Pharmaceutical industry, NSCLC, Filippo Jacobio

The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.

Key Points: 
  • The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.
  • Jacobio presented results of a Phase I/IIa study of glecirasib in combination with JAB-3312.
  • The ORR was 86.7% (13/15) in the dose group[1] of 800 mg glecirasib in combination with 2 mg JAB-3312.
  • "The data provides the basis for the registrational clinical study of glecirasib in combination with SHP2 inhibitor.

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

Retrieved on: 
Wednesday, March 22, 2023
Filippo Jacobio, CD73, Trial of the century, Patient, Merck, Merck & Co., Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Immunosuppression, Tumor microenvironment, Pharmaceutical industry

BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Key Points: 
  • BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
  • The clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA for the treatment of advanced solid tumors.
  • "The CD73 monoclonal antibody is Jacobio's first large molecule project to enter the clinic.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

Retrieved on: 
Thursday, October 13, 2022
Blood, Merck Serono, Health, Immunoglobulin G, EGFR, Cetuximab, STK11, Electronics, Head, Neck, Neoplasm, Intelligence, Patient, Gene editing, Eli Lilly and Company, RAS, Colorectal cancer, KRAS, Solution, RB, Trial of the century, Company, ImClone Systems, PD-1, SHP2, MYC, Radiation, Entrepreneurship, Merck Millipore, Pharmaceutical industry, Merck, Filippo Jacobio

This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

Key Points: 
  • This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
  • Jacobio is the sponsor of the combination study, and Merck will provide cetuximab for clinical trials in China and Europe under the collaboration agreement.
  • We look forward to new treatment options for patients through our collaboration with Merck," said Dr. WANG Yinxiang,Chairman and Chief Executive Officer of Jacobio.
  • Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health.

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

Retrieved on: 
Monday, January 17, 2022
Nature, Patient, Food and Drug Administration, News, Apoptosis, Social conditions in Honduras, SHP2, Drug resistance, Filippo Jacobio, Breast cancer, Solution, IND, Squamous cell carcinoma, Company, Environment, Multimedia, Food, Aurora A kinase, Aurora B kinase, FDA, Investigational New Drug, KRAS, Pharmaceutical industry

BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US.

Key Points: 
  • BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US.
  • Jacobio plans to initiate a Phase I/IIa clinical trial in patients with advanced solid tumors in the US.
  • JAB-2485 can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumor growth.
  • Jacobio's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stagein the United States.